The clinical-stage biopharma priced new shares at a 14% discount to fund progress on three CNS drug programmes and installed Turner Pope as broker.

"These early results suggest that SVN-015 may have the potential to deliver the intended transporter pharmacology while avoiding some of the cardiac ion-channel liabilities associated with previous compounds in this area," said chief executive Anthony Tennyson.

Bridging data show SVN-002's sublingual-buccal delivery can match intranasal esketamine exposure, clearing a critical hurdle on the path to a U.S. IND submission.

Solvonis Therapeutics said it will prioritise completing Phase 3 of SVN-001 after reporting cash and cash equivalents of £1.720 million at the year ended 31 December 2025 and repositioning as a focused CNS biopharmaceutical business.

Solvonis said the USPTO issued the new patent on 7 April 2, protecting a chemically distinct monoamine modulator series and extending its PTSD intellectual‑property estate.